FDA Approves Intranasal DHE (Trudhesa) for Acute Migraine
The US Food and Drug Administration (FDA) has approved an intranasal formulation of dihydroergotamine mesylate (DHE) for the acute treatment
Read more
Intranasal DHE Safe for Acute Migraine: STOP 301 Published
An intranasal formulation of dihydroergotamine (DHE) for the acute treatment of migraine is safe and well tolerated, new research suggests.
Read more
Intranasal Third-Generation CGRP Effective for Acute Migraine
Intranasal zavegepant, a third-generation calcitonin gene-related peptide (CGRP) receptor agonist, is effective and well tolerated in the treatment of acute
Read more